Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462391 | 1.00 | TDP1 (0.48) | TDP1KMT2AMEN1HTTGAA | |
| Hydrochloric Acid SCHEMBL5778836 | 0.97 | TDP1 (0.46) | TDP1KMT2AMEN1HTTGAA | |
| SCHEMBL9476338 | 0.81 | ALDH1A1 (0.46) | TDP1KMT2AMEN1HTTGAA | |
| SCHEMBL38657291 | 0.79 | TDP1 (0.48) | TDP1KMT2AMEN1GAAHSP90AB1 | |
| SCHEMBL26694654 | 0.79 | TDP1 (0.48) | TDP1KMT2AMEN1GAAHSP90AB1 | |
| SCHEMBL25292365 | 0.75 | GAA (0.40) | TDP1KMT2AMEN1HTTGAA | |
| SCHEMBL5746102 | 0.75 | ALDH1A1 (0.40) | TDP1KMT2AMEN1HTTGAA | |
| SCHEMBL19049647 | 0.75 | TDP1 (0.44) | TDP1KMT2AGAAHSP90AB1HSP90AA1 | |
| SCHEMBL18260463 | 0.75 | TDP1 (0.44) | TDP1KMT2AMEN1GAAHSP90AB1 | |
| SCHEMBL30421541 | 0.75 | ALDH1A1 (0.40) | TDP1KMT2AMEN1HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20250325544-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250281487-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250275971-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275972-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| US-12285429-B2 | CDK inhibitors | GENENTECH, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20250064806-A1 | CDK INHIBITORS | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-1995018616-A2 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARM INC (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0505893-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1992-09-30 | — | — | EP | disclosed |
| EP-0255217-B1 | FUSED IMIDAZOHETEROCYCLIC COMPOUNDS | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-01-22 | — | — | EP | disclosed |
| US-4948800-A | MUSCLE RELAXANTS; ANTICONVULSANTS; ANXIOLYTIC AGENTS; 3-HYDROXYALKYL-PYRIDO(4,5-B OR-C)IMIDAZOLE COMPOUNDS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-14 | — | — | US | disclosed |
| US-4914109-A | ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-04-03 | — | — | US | disclosed |
| US-4873251-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-10 | — | — | US | disclosed |
| US-4824951-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-04-25 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0255217-A1 | Fused imidazoheterocyclic compounds | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-02-03 | — | — | EP | disclosed |
| US-3935195-A | FLUORESCENT DYE | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | TDP1 697/4885KMT2A 1950/4885MEN1 3486/4885 |
| US-20250281487-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | TDP1 968/4885KMT2A 178/4885MEN1 1620/4885 |
| US-20250064806-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | TDP1 1013/4885KMT2A 147/4885MEN1 2306/4885 |
| US-12285429-B2 | CDK inhibitors | CDK9, CDK3, CDKL1 | TDP1 844/4885KMT2A 151/4885MEN1 1846/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | TDP1 1007/4885KMT2A 1094/4885MEN1 3571/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | TDP1 2127/4885KMT2A 2514/4885MEN1 4829/4885 |
| US-20250325544-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | TDP1 968/4885KMT2A 178/4885MEN1 1620/4885 |
| US-20250275972-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | TDP1 1013/4885KMT2A 147/4885MEN1 2306/4885 |
| US-20250275971-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | TDP1 968/4885KMT2A 178/4885MEN1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.